Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - Here's Why

Key Points

• Trading volume increased 4% to approximately 231,111 shares, while Telix Pharmaceuticals shares rose to $11.555 from a previous close of $11.45.
• Analyst sentiment remains positive, with an average rating of “Buy” and a consensus price target of $20.50; recent targets include $20 from HC Wainwright and $22 from Wedbush.
• Institutional interest has strengthened, with firms including XY Capital, Bank of America, and Private Advisor Group significantly increasing their positions in the company.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw an uptick in trading volume on Monday. Approximately 231,111 shares changed hands during trading, an increase of 4% from the previous session's volume of 221,552 shares. The stock last traded at $11.5550 and had previously closed at $11.45.

Wall Street Analysts Forecast Growth

TLX has been the subject of a number of analyst reports. Citigroup reiterated a "buy" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Weiss Ratings raised shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, August 21st. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Friday. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research note on Monday, September 21st. Finally, Wedbush reiterated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $20.50.

Telix Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. The stock has a 50-day moving average price of $11.35 and a 200 day moving average price of $10.50.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. XY Capital Ltd grew its position in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company's stock worth $822,000 after buying an additional 58,739 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals during the second quarter valued at $1,731,000. Bank of America Corp DE raised its stake in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock worth $96,000 after buying an additional 8,423 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock valued at $2,775,000 after purchasing an additional 39,400 shares in the last quarter. Finally, Private Advisor Group LLC raised its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after acquiring an additional 128,070 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.